A positive direct antiglobulin test (DAT) may earn one mark—and still leave an acute hemolytic transfusion reaction (AHTR) short answer incomplete. A strong response connects three questions: Is red-cell destruction occurring? Is there evidence of immune incompatibility? Has the reaction caused organ injury or coagulopathy? Treating one result as the whole diagnosis is the common reasoning error.
In practice, suspected AHTR is urgent: stop the transfusion, do not restart it unless the transfusion service clears it, and notify the transfusion service while the patient is assessed. For exam preparation, focus on organizing the laboratory workup, not memorizing a disconnected list.
Organize the workup around three questions
Where available, the transfusion service compares a pre-transfusion sample with a new post-reaction sample, checks identification and compatibility records, and evaluates the implicated unit. Follow local procedures for sample collection and handling.
| Question | Investigations | Expected findings and limits |
|---|---|---|
| Is there evidence of hemolysis? | Inspect plasma; CBC and blood film; LDH, bilirubin, haptoglobin and, if available, plasma-free hemoglobin; urinalysis | Pink or red plasma, increased LDH and indirect bilirubin, reduced haptoglobin, and possible hemoglobinemia or hemoglobinuria support hemolysis. Hemoglobin may fall, but interpret the trend against the pre-transfusion result. |
| Is immune incompatibility supported? | DAT on pre- and post-transfusion samples; repeat ABO/Rh typing of patient and unit; antibody screen, with identification if an antibody is detected; repeat serologic crossmatch | A new positive DAT, ABO discrepancy, newly identified red-cell antibody, or incompatible crossmatch may support an immune cause. No single result explains the entire event on its own. |
| Are complications developing? | Creatinine and electrolytes; platelet count; PT, aPTT, fibrinogen and D-dimer when the reaction is severe | Rising creatinine or electrolyte disturbance may indicate kidney injury. Thrombocytopenia, prolonged clotting times, low fibrinogen and elevated D-dimer support DIC; they are not expected in every reaction. |
First establish the hemolysis pattern
A useful short-answer cluster is plasma appearance, blood-count trend, hemolysis markers and urine. Pink or red plasma after centrifugation suggests free hemoglobin. LDH and indirect bilirubin may rise, while haptoglobin falls as it binds free hemoglobin. A urine dip positive for heme with few or no red cells on microscopy supports pigmenturia—often hemoglobin in this setting—but is not diagnostic alone.
Do not turn supportive findings into mandatory ones. The timing and degree of change vary, and a hemoglobin result should be compared with the patient’s baseline and transfusion history. Plasma discoloration also needs context: sample and product handling matter, so it should not replace the rest of the evaluation.
Use the DAT to answer a narrower question
The DAT detects immunoglobulin and/or complement attached to red cells. A newly positive post-transfusion DAT supports immune coating, but it does not by itself prove that transfusion caused clinically important red-cell destruction. Compare it with the pre-transfusion result and interpret it alongside the antibody screen, crossmatch and patient’s hemolysis findings.
A negative DAT does not make clear hemolysis disappear. Physical or chemical injury to red cells can cause non-immune hemolysis without a new immune signal. If the DAT is positive, the transfusion service may use an eluate and further antibody testing to investigate the specificity. This is why the safest exam wording is that the DAT supports immune-mediated hemolysis, not that it alone confirms AHTR.
Keep complication tests in their lane
Include renal function because intravascular hemolysis can be accompanied by hemoglobinuria and kidney injury; creatinine may not rise immediately. Add coagulation studies when the patient is seriously ill or DIC is suspected. Low platelets, prolonged PT or aPTT, low fibrinogen and raised D-dimer describe a possible complication—not a required signature of every reaction.
If fever, rigors or shock raise concern for bacterial contamination, cultures of the patient and implicated unit may be appropriate. That investigates an important alternative or concurrent problem; it is not a test that confirms hemolysis. In an SAQ, label such tests as targeted rather than presenting every possible investigation as mandatory.
A five-minute retrieval exercise
Close your notes. In 90 seconds, write the three questions above from memory. Then spend two minutes listing the investigations and expected patterns under each. Keep the DAT in the compatibility section, not as a substitute for evidence of hemolysis.
Use the final 90 seconds on two variations:
- The post-transfusion DAT is positive, but there is no convincing change in hemoglobin, plasma appearance or hemolysis markers. What does the DAT support, and what does it not establish? Check your answer: it supports red-cell coating; by itself it does not prove clinically significant transfusion-related hemolysis.
- Hemolysis is evident, but the DAT is negative. Should you stop the investigation? No. Consider non-immune injury and have the transfusion service reconcile the serology, samples and implicated unit.
Tomorrow, retrieve only the three-part structure and the two distinctions you missed before reviewing your notes. Recalling the organization after a gap tests whether you can produce the answer—not merely recognize it while rereading.
Practical takeaways
- Organize the answer as hemolysis, incompatibility, complications.
- Name the expected direction of change: LDH and indirect bilirubin up; haptoglobin down; possible hemoglobinemia or hemoglobinuria.
- Interpret DAT against the pre-transfusion result and the full serologic workup.
- Present coagulation studies and cultures as targeted investigations, not universal confirmation tests.
